Q4 2024 · 13F-HR
B Group, Inc.holdings as filed
Filed 2025-02-14 · accession 0001420506-25-000436
$163.6M
Reported value
18
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 46090E953 | — | INVESCO QQQ TR | $56.2M | 34.4% | 110,000 | Common | SOLE |
| 000899104 | ADMA | ADMA BIOLOGICS INC | $39.2M | 24.0% | 2,287,542 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $24.2M | 14.8% | 350,000 | Common | SOLE |
| 98887Q104 | ZLAB | ZAI LAB LTD | $10.5M | 6.40% | 400,000 | Common | SOLE |
| 462260100 | IOVA | IOVANCE BIOTHERAPEUTICS INC | $7.3M | 4.49% | 992,000 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $7.2M | 4.42% | 260,000 | Common | SOLE |
| 15117K103 | CLLS | CELLECTIS S A | $5.5M | 3.39% | 3,081,501 | Common | SOLE |
| 05153U107 | AURA | AURA BIOSCIENCES INC | $3.9M | 2.37% | 472,576 | Common | SOLE |
| 82657M105 | SGHT | SIGHT SCIENCES INC | $2.3M | 1.40% | 629,370 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $1.7M | 1.02% | 965,556 | Common | SOLE |
| 90400D908 | — | ULTRAGENYX PHARMACEUTICAL IN | $1.2M | 0.76% | 29,500 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $1.2M | 0.71% | 50,000 | Common | SOLE |
| 045396207 | ASMB | ASSEMBLY BIOSCIENCES INC | $799,273 | 0.49% | 50,651 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $679,500 | 0.42% | 15,000 | Common | SOLE |
| 221015950 | — | CORVUS PHARMACEUTICALS INC | $535,000 | 0.33% | 100,000 | Common | SOLE |
| 09075V102 | BNTX | BIONTECH SE | $398,825 | 0.24% | 3,500 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $387,800 | 0.24% | 20,000 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $319,564 | 0.20% | 7,596 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.